Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Up 94.2% in December

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 482,725 shares, a growth of 94.2% from the December 15th total of 248,611 shares. Based on an average trading volume of 835,806 shares, the short-interest ratio is currently 0.6 days. Currently, 0.9% of the company’s shares are sold short. Currently, 0.9% of the company’s shares are sold short. Based on an average trading volume of 835,806 shares, the short-interest ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Klotho Neurosciences

A hedge fund recently bought a new stake in Klotho Neurosciences stock. Jane Street Group LLC bought a new stake in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences as of its most recent SEC filing. Institutional investors and hedge funds own 20.07% of the company’s stock.

Klotho Neurosciences Stock Performance

NASDAQ:KLTO traded up $0.01 on Friday, hitting $0.33. The stock had a trading volume of 439,483 shares, compared to its average volume of 685,789. Klotho Neurosciences has a 1 year low of $0.11 and a 1 year high of $3.91. The firm’s fifty day simple moving average is $0.40 and its two-hundred day simple moving average is $0.64. The stock has a market cap of $24.12 million, a P/E ratio of -1.03 and a beta of 10.27.

Klotho Neurosciences (NASDAQ:KLTO) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.05) EPS for the quarter.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.